GUIDED THERAPEUTCS (GTHP) Stock Price, News & Analysis

Guided Therapeutics, Inc. (OTCQB: GTHP) operates in the surgical and medical instrument manufacturing industry and focuses on technologies for the early detection of disease at the cellular level. According to the company, it is the maker of a rapid and painless testing platform based on its patented biophotonic technology, which utilizes light for early disease detection. Its activities are aligned with the broader manufacturing sector for medical devices, with an emphasis on diagnostic applications.

The company’s first product is the LuViva® Advanced Cervical Scan, described as a non-invasive device used to detect cervical disease instantly and at the point of care. Guided Therapeutics reports that, in a multi-center clinical trial with women at risk for cervical disease, its technology was able to detect cervical cancer up to two years earlier than conventional modalities, based on published reports. The company also notes that LuViva is designed as a rapid and painless testing platform for cervical cancer detection that is based on its biophotonic approach.

Guided Therapeutics states that LuViva is intended to address limitations of the current standard of care for cervical cancer detection, which typically involves Pap and HPV testing followed by biopsies guided by colposcopy. In communications about its U.S. FDA pivotal clinical trial, the company highlights preliminary analyses indicating that a substantial percentage of early cervical precancers may be missed under current practice for women referred to biopsy based on abnormal Pap and/or HPV results. The company’s stated study goal is to demonstrate that LuViva can detect precancers and cancers that are not identified by these standard methods.

The company reports that LuViva has been evaluated in multi-center clinical settings and that previous studies have shown the technology can detect a majority of early precancers and cancers. Guided Therapeutics also notes that, in its U.S. FDA study, LuViva has been designated a non-significant risk device, and that no adverse events linked to the use of LuViva were reported in the context described. In addition, the LuViva Advanced Cervical Scan is characterized by the company as an investigational device in the United States and is limited by federal law to investigational use.

Guided Therapeutics’ disclosures also describe international activity related to LuViva. The company reports work with partners and distributors in locations including China and Indonesia to supply LuViva devices and single-use components. For example, it has discussed agreements and purchase orders with distribution partners in Chinese provinces and an initial shipment of systems and disposables for use in the government healthcare system in Sulawesi, Indonesia. These arrangements, as described by the company, are focused on deploying LuViva in settings where cervical cancer screening is performed, including hospitals and healthcare systems.

In China, Guided Therapeutics states that its partner Shandong Yaohua Medical Instrument Corporation (SMI) filed an application with the Chinese National Medical Products Administration (NMPA) for LuViva. The company reports that this application included results from women tested at multiple medical institutions in China and that the study results met or exceeded thresholds defined in the study protocol. The company further notes that the filing with NMPA is tied to an ongoing working relationship with SMI that contemplates milestones and minimum payments for devices, disposables, services and royalties over a multi-year period, subject to regulatory approval and commercial progress.

Guided Therapeutics also describes commercial arrangements with Hangzhou Dongye Medical Technology Company Ltd (HDMT), which it identifies as an exclusive gynecology products provider for a group of hospitals in Zhejiang Province that perform a large number of cervical cancer screenings annually. According to the company, HDMT has placed purchase orders for LuViva systems and components, and Guided Therapeutics has reported shipments and related payments under these agreements. In addition, the company has announced an initial supply agreement with Yuanshuo Medical Instruments Corporation (YMIC) in Jiangsu province, China, for LuViva devices and single-use components.

Across these disclosures, Guided Therapeutics presents itself as a medical device manufacturer focused on biophotonic technology for cervical disease detection. The company emphasizes non-invasive, point-of-care testing and the potential to identify cervical precancer and cancer earlier than conventional approaches. It also highlights its use of clinical trials, regulatory submissions, and distribution partnerships as key elements in the development and commercialization of LuViva.

Business focus and technology

Core focus: Guided Therapeutics concentrates on diagnostic devices for cervical disease detection. Its platform is described as rapid, painless and based on patented biophotonic technology that uses light to assess tissue at the cellular level.

Primary product: The LuViva Advanced Cervical Scan is characterized by the company as a non-invasive device that can be used at the point of care to detect cervical disease instantly. The company indicates that LuViva is designed to complement or improve upon existing screening pathways that rely on Pap tests, HPV testing, colposcopy and biopsy.

Clinical and regulatory context: Guided Therapeutics reports that LuViva has been evaluated in multi-center clinical trials, including a pivotal U.S. FDA study and a study in China that supported an application to the NMPA. The company’s communications describe performance metrics such as sensitivity and specificity for detecting cervical precancers and cancers, and they discuss how these metrics relate to the potential to reduce missed disease and unnecessary biopsies.

International distribution and commercialization

Guided Therapeutics’ disclosures describe distribution and commercialization efforts for LuViva outside the United States. In China, the company references its collaboration with SMI on regulatory approval and commercialization, as well as purchase orders and supply agreements with HDMT and YMIC for devices and single-use components. In Indonesia, the company has reported an order and full payment for LuViva systems and single-use cervical guides intended for use in the government healthcare system in Sulawesi.

These arrangements, as described by Guided Therapeutics, involve supplying LuViva devices and related disposables to healthcare providers and distributors in regions where cervical cancer screening is conducted. The company presents these activities as part of its broader effort to deploy its technology in clinical practice, subject to local regulatory requirements.

Regulatory status and limitations

Guided Therapeutics consistently notes that the LuViva Advanced Cervical Scan is an investigational device in the United States and is limited by federal law to investigational use. The company also references risk factors in its public communications, including uncertainties related to regulatory approval of products and the ability to commercialize its technology or continue as a going concern, as more fully described in its reports filed with the SEC.